Sooph

Entrepreneur, Trader - #OCUGEN faithful

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

RP is a genetic condition that leads to progressive vision loss over time. #OCU400 is an investigational modifier #genetherapy designed as a potential one-time treatment for people living with RP. #RetinitisPigmentosa #Ocugen

Learn more: https://t.co/ykiBbfm4mp

[Elon Musk @elonmusk]

Interesting

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

What makes #OCU400 different?

OCU400 is designed to address multiple RP mutations through a potential one-time therapy.

Follow us for updates as we advance OCU400 toward a planned BLA submission this year.

#RetinitisPigmentosa #GeneTherapy $OCGN

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ +6 letter gain in visual acuity

Hear from an OCU410ST clinical trial participant: https://t.co/znh5I8UL9R

$OCGN

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen Patient Engagement @OcugenPE]

What is #RetinitisPigmentosa (RP)?

RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN

[HODOR @Maximus_Holla]

$TENX 1st green close since 1941!

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

100,000+ people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, with early promising data.

Follow Ocugen and be part of something groundbreaking. #Biotech #Genetherapy $OCGN

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.

Learn more: https://t.co/7nSj5EJkPZ

#GeneTherapy #Biotech #FinancialUpdate $OCGN

[IT @IncredibleTrade]

$SPX 7344 to 7400 .. One of our members was spot-on calling the bottom at 7339!

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen Patient Engagement @OcugenPE]

Today, CEO @drsmusunuri announced 1Q 2026 update:
• Cash runway into 2028
• Positive #OCU410 data
• Enrollment complete for #OCU400 & #OCU410ST
• Progress toward BLA filings
Read: https://t.co/nwI7GLAkh4
#EarningsUpdate #Genetherapy $OCGN

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen Patient Engagement @OcugenPE]

Susan, an #OCU410ST participant, saw stabilization in her treated eye after #Stargardtdisease treatment, while the untreated eye declined. Now in Phase 2/3, OCU410ST could become the first approved therapy for Stargardt disease. Follow us for updates.

[Cheds Trading @BigCheds]

@DuuuvalDuuudes Way worse. I made a fool of myself

[TheUrbanFarmer @NattaCop]

$OCGN Just a heads up fam, this is not some random trip, convention, or basic business meeting. This is big. Way bigger than most people probably realize.

The US government selected Ocugen and brought them directly into rooms full of investors, partners, buyers, decision makers, and foreign stakeholders who can shape commercial and regulatory paths overseas.

The doors to international partnerships, regional deals, strategic investors, distribution relationships, and future market access have opened for Ocugen.

When you own a company with platform technology, broad multiplying applications, life changing data, a stellar safety profile, and assets aimed at massive unmet needs across global markets, you do not need to obsess over daily movements, candles, or whatever pattern you see on a chart. You just sit back and enjoy being one of the lucky few who saw and bought the next global biotech leader before anyone else did. 🍻

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

Honored to join the U.S. @CommerceGov Certified Trade Mission to Singapore with https://t.co/MFNdMesYmg, connecting with investors and industry leaders to advance cross-border collaboration. Looking forward to continuing the conversation globally. @drsmusunuri #TradeMission

[Sooph @Soophenomina]

$OCGN 👀👀👏🏻👏🏻

[Ocugen @Ocugen]

Phase 2 Update: A 31% reduction in GA lesion growth was observed with #OCU410 (medium dose) and a 27% EZ preservation in treated v. control supporting medium dose as optimal in Phase 3. #GeographicAtrophy #PatientImpact

Latest corp. presentation: https://t.co/hIYAlBqgZQ

[Billythekid123 @B1llyTh2K3d]

5 years ago we were stonewalled out of the Covid vaccine market. If you were there for it, you’d know it was Fauci’s doing entirely. $OCGN

Today we stand stronger than ever. On the verge of our first BLA, a nasal vaccine capable of being outfitted for anything and NeoCart. 😉🤙

[Erick Alfαro @erickalfaro]

Iran ultimatum tomorrow, NFP bomb, $NKE earnings — volatility explodes

🔴 Apr 05 — Iran Ultimatum:
48hr deadline — spy/vix dump risk

⚪ Apr 07 — Labor Market Data:
jolts/adp/nfp — softer print = extend selloff

🟢 Apr 13 — LVMH & $NKE Earnings:
nike q4 rev down 2-4%, $60 calls hot

🟢 Apr 30 — Iran De-Escalation:
trump: war ends 2-3wks, oil $200 risk

🔴 May 31 — DHS Shutdown Risk:
funding fight, senate resistance

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen @drsmusunuri @drhumaqamar
👏👏👏

[Sooph @Soophenomina]

$OCGN👀👀👏🏻👏🏻

https://t.co/U3cUiN3gJ7

[Shankar Musunuri @drsmusunuri]

One step closer to serving Stargardt patients! Big thanks to our dedicated Ocugen team.